New drug AMG 436 targets tough cancers in early trial

NCT ID NCT07403721

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 6 times

Summary

This early-phase trial is testing a new drug called AMG 436, alone or with other cancer treatments, in adults with advanced solid tumors that have high microsatellite instability or mismatch repair deficiency. The main goals are to check safety, find the best dose, and see how the drug moves through the body. About 464 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AMG 436
What this could lead to: If successful, this could lead to a new treatment option for people with hard-to-treat cancers that have specific genetic features.
What could go wrong: This is an early phase 1 trial focused on safety and dosing, so it is unknown if AMG 436 will effectively shrink tumors or improve survival. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC OR LOCALLY ADVANCED SOLID TUMORS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCHED REPAIR DEFICIENCY (DMMR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC OR LOCALLY ADVANCED SOLID TUMORS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCHED REPAIR DEFICIENCY (DMMR)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Aichi Cancer Center
RECRUITING

Nagoya, Aichi-ken, 464-8681, Japan
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Calvary Mater Newcastle Hospital
RECRUITING

Waratah, New South Wales, 2298, Australia
City of Hope Orange County Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
Clinica Universidad de Navarra
RECRUITING

Madrid, 28027, Spain
Community Health Network MD Anderson Cancer Center - North
RECRUITING

Indianapolis, Indiana, 46250, United States
Gustave Roussy
RECRUITING

Villejuif, 94805, France
Hopital Saint Antoine
RECRUITING

Paris, 75012, France
Hospital Clinic i Provincial de Barcelona
RECRUITING

Barcelona, Catalonia, 08036, Spain
Hospital Universitari Vall d Hebron
RECRUITING

Barcelona, Catalonia, 08035, Spain
Midwestern Regional Medical Center dba City of Hope Chicago
RECRUITING

Zion, Illinois, 60099, United States
National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa-shi, Chiba, 277-8577, Japan
New England Cancer Specialists
RECRUITING

Westbrook, Maine, 04092, United States
Next Oncology - Dallas
RECRUITING

Irving, Texas, 75039, United States
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 1Z5, Canada
Sun Yat-Sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
Taipei Veterans General Hospital
RECRUITING

Taipei, 11217, Taiwan
Tennessee Oncology PLLC
RECRUITING

Nashville, Tennessee, 37203, United States
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
RECRUITING

Koto-ku, Tokyo, 135-8550, Japan
Universitair Ziekenhuis Gent
RECRUITING

Ghent, 9000, Belgium
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
RECRUITING

Brussels, 1200, Belgium
Zhongshan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China